NCT04291703终止2 期
Low Dose Antithymocyte Globulin (ATG) to Delay or Prevent Progression to Stage 3 T1D
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)44 个研究点 分布在 2 个国家目标入组 2 人开始时间: 2023年11月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 2
- 试验地点
- 44
- 主要终点
- Progression to Stage 3 T1D
研究概览
简要总结
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D. This study did not meet enrollment targets and was terminated approximately 13 months after the first participant enrolled.
详细描述
This study has a planned enrollment period of 4 years and once the enrollment phase has concluded, an additional two years of follow-up visits will be conducted for all participants. Participants enrolled in the first year of the study can expect to complete follow-up visits for approximately four additional years if progression to stage 3 (Type 1 Diabetes Onset) does not occur. Participant follow-up visits after the treatment phase of the study includes general assessments (medical history, physical exam, medications and adverse events) and laboratory assessments to determine current health status and glucose tolerance. This study was terminated early due to lack of enrollment and infeasibility of attaining enrollment goals. Follow-up of enrolled participants continued through study termination, approximately 13 months after the first participant enrolled.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
The randomization method will be stratified by TrialNet study site. The participants will not be informed regarding the intervention assignment until the end of the study. The investigator and clinic personnel will also be masked as to study assignment. Laboratories performing assays for this protocol will be masked as to the identity of biological material to be studied.
入排标准
- 年龄范围
- 6 Years 至 34 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing to provide informed consent or have a parent or legal guardian provide informed consent when the subject is <18 years of age.
- •Age greater than or equal to 6 and < 35 years
- •At least two or more diabetes-related biochemical autoantibodies (mIAA, GADA, ICA, IA-2A, ZnT8A) present on the same sample. In the absence of other antibodies, ICA and GADA positivity alone will not suffice for eligibility in this trial.
- •Weight greater than the 5th percentile for age and sex.
- •BMI < 95th and > 5th percentile for age for those under age 18 years and < 30 and > 15 for adults (≥ 18)
- •ADA Stage 2 criteria* AND at least one of the following high-risk markers (occurring at the same visit) within 7 weeks (52 days) of randomization, defined below (for defining a 2-year 50% risk for progression to Stage 3 T1D):
- •a. HbA1c ≥ 5.7 and <6.5% b. Index60 ≥ 1.4 i. Index60 = 0.3695 × (log fasting C-peptide [ng/mL]) + 0.0165 × 60-min glucose (mg/dL) - 0.3644 × 60-min C-peptide (ng/mL) c. DPTRS ≥ 7.4 DPTRS = (1.57 x log BMI) - (0.06 x age) + (0.81 x glucose sum from 30 to 120 min/100) - (0.85 x C-peptide sum from 30 to 120 min/10) + (0.48 x log fasting C-peptide)
- •*Dysglycemia is defined as 2-hr glucose ≥ 140 and <200 mg/dL or fasting glucose ≥ 110 and <126 or 30, 60, or 90 minute glucose ≥ 200 mg/dL from OGTT
- •CMV and/or EBV seronegative participants must be CMV and EBV PCR negative within 30 days of randomization and may not have had signs or symptoms of a CMV or EBV-compatible illness lasting longer than 7 days within 30 days of randomization.
- •CMV seropositive participants must be CMV PCR negative and all EBV seropositive participants must have EBV PCR < 2,000 IU/mL within 30 days of randomization and may not have had signs or symptoms of a CMV or EBV-compatible illness lasting longer than 7 days within 30 days of randomization.
- •Seated blood pressure less than 130/80 mmHg for participants ≥ 18 years. For participants < 18 years seated blood pressure less than 95th percentile for age, sex and height.
- •Be at least 4 weeks from last live immunization.
- •Participants are required to receive non-live influenza vaccination at least 2 weeks prior to randomization when vaccine for the current or upcoming flu season is available.
- •Participants must have a negative COVID-19 test within 7 days of the first day of treatment if otherwise eligible.
- •Willingness to comply with study directed social distancing and protection from SARS-Cov-2 infection.
- •Be willing to forgo vaccines (other than killed influenza) during the 3 months after study drug treatment period (Days 0 and 1).
- •Be up to date on all recommended vaccinations based on age of participant*
- •With the exception of stage 2 T1D, participants must be healthy, as defined by absence of any other untreated diagnoses that the protocol committee deems to be a potential confounder.
- •If a female participant with reproductive potential, willing to avoid pregnancy (abstinence or adequate contraceptive method) through the completion of the study infusions and up to 3 months after study drug administration and undergo pregnancy testing prior to each study visit.
- •Must be residing or have accommodations within 1 hour of the infusion site during the two days of study drug infusions and must be within 1 hour of a medical care facility for 1 day after completion of infusion
- •Participants must live in a location with rapid access to emergency medical services.
- •Adult participants must be fully immunized. Pediatric participants who have not completed their primary vaccination schedule must receive all vaccinations allowable per the national/country-specific immunization guidelines for their current age prior to study drug delivery. Any remaining vaccinations should be given and continue per the schedule at least 3 months after study drug is administered. For COVID-19 vaccination, all participants will be strongly encouraged to be up-to-date with COVID-19 vaccine(s) as indicated by country-specific guidelines at least 2 weeks prior to randomization.
排除标准
- •Immunodeficiency or clinically significant chronic lymphopenia: (Leukopenia (< 3,000 leukocytes /μL), neutropenia (<1,500 neutrophils/μL), lymphopenia (<800 lymphocytes/μL), thrombocytopenia (<100,000 platelets/μL).
- •Hemoglobin less than 13.5 g/dL for adult men and less than 12 g/dL for adult females and less than 11 g/dL for participants under age 18
- •Active signs or symptoms of acute infection at the time of randomization including SARS-Cov-
- •Uncontrolled autoimmune thyroid disease and/or celiac disease (participants must be well controlled for the previous 6 months).
- •Evidence of prior or current tuberculosis infection as assessed interferon gamma release assay (QuantiFERON).
- •Currently pregnant or lactating or anticipate getting pregnant within the study period.
- •Require use of other immunosuppressive agents including chronic use of systemic steroids.
- •Evidence of current or past HIV or Hepatitis B or current Hepatitis C infection.
- •Any complicating medical issues or abnormal clinical laboratory results that may interfere with study conduct, or cause increased risk to include pre-existing cardiac disease, COPD, sickle cell disease, neurological disease, or blood count abnormalities.
- •A history of malignancies other than of skin.
- •Evidence of liver dysfunction with AST or ALT outside of the reference range.
- •Evidence of renal dysfunction with creatinine outside of the reference range.
- •Increased bilirubin (total and direct) outside of the normal limit (Participants with documentation of Gilbert's Disease permitted).
- •Vaccination with a live virus within the last 4 weeks.
- •Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within 7 days of screening
- •Prior treatment with Teplizumab (either in a previous clinical trial or clinically).
- •Has participated in a clinical trial for diabetes prevention previously and received active study agent within 3 months of randomization.
- •Known allergy to ATG or any product excipient
- •Prior treatment with ATG or known allergy to rabbit-derived products or to any product excipient
- •Prior adverse reactions to heparin.
- •Any condition that in the investigator's opinion may adversely affect study participation will be reviewed by the Study Chair to ensure consistency and adjudicate whether or not the subject may compromise the study results
- •Any screening/baseline laboratory result not otherwise stated out of normal reference range and/or medical history that may increase the risk of the subject's participation in this trial.
- •Previously diagnosed with Stage 3 TID according to ADA criteria (see Appendix 3 for Criteria for diagnosis of diabetes)
研究组 & 干预措施
Antithymocyte globulin (ATG)
Experimental
Participants assigned to this arm will receive ATG
干预措施: Antithymocyte Globulin (Drug)
Placebo
Placebo Comparator
Participants assigned to this arm will receive saline (placebo) to match ATG infusion
干预措施: Placebo (for ATG) (Drug)
结局指标
主要结局
Progression to Stage 3 T1D
时间窗: 5 years
The primary outcome is the elapsed time from random treatment assignment to the development of diabetes or time of last contact among those randomized
次要结局
未报告次要终点
研究者
研究点 (44)
Loading locations...
相似试验
已完成
2 期
Antithymocyte Globulin and Cyclosporine to Treat MyelodysplasiaMyelodysplastic SyndromeNCT00005937Neal Young, M.D.42
已完成
不适用
Low Dose Thymoglobulin to Protect Kidney Function After Liver TransplantLiver TransplantationNCT00970073The Cleveland Clinic30
已完成
2 期
ATG-GCSF in New Onset Type 1 DiabetesDiabetes Mellitus, Type 1NCT02215200National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)89
进行中（未招募）
2 期
ATG Plus PTCy vs ATG for CGVHD ProphylaxisMyelodysplasiaChronic Graft-versus-host-diseaseAcute LeukemiaNCT04202835McMaster University80
终止
早期 1 期
Research Study of ATG and Rituximab in Renal TransplantationRenal Transplant RecipientsNCT01318915National Institute of Allergy and Infectious Diseases (NIAID)10